General

An investigative report on how large language models misrepresent prescription drugs, what that costs manufacturers, and why most brand teams […]

Physicians are increasingly asking AI chatbots how to dose drugs, manage contraindications, and choose between therapies. The AI answers. The

If you want to understand how patients actually think about switching between similar drugs, don’t look for clean “Drug A

Scroll through enough patient questions and a pattern emerges: people aren’t just taking drugs—they’re tuning them. Combining, stretching, substituting. Off-label

If you want to know when adherence breaks, don’t look at refill data. That’s the autopsy. The early signals show

The pharmaceutical industry has spent decades building brand reputations through clinical trials, physician detailing, and tightly controlled messaging. That infrastructure

Why Pharmaceutical Brands Must Shift from Social Listening to AI Monitoring — Before Regulators Do The clinical detail rep used

How pharmaceutical brands are losing control of patient conversations, clinical narratives, and competitive positioning inside the black box of generative

How pharmaceutical companies are using AI surveillance tools to protect brand integrity, stay ahead of the FDA, and decode what

How large language models are quietly reshaping brand exposure, regulatory liability, and the future of pharmacovigilance The alert came from

Drug companies spend billions crafting brand narratives. AI is rewriting them in real time — and most manufacturers have no

The pharmacovigilance team at a mid-size specialty pharma company discovered the problem during a routine brand audit. Patients searching for